Palliative chemotherapy for pulmonary pleomorphic carcinoma

Lung Cancer

Volumn 58, Issue 1, 2007, Pages 112-115

  Bae, Hyun Mi ^a   Min, Hye Sook ^b   Lee, Se Hoon ^a,b   Kim, Dong Wan ^a,b   Chung, Doo Hyun ^b   Lee, Jong Seok ^a   Kim, Young Whan ^a   Heo, Dae Seog ^a,b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

Chemotherapy; Lung cancer; Palliative; Pleomorphic carcinoma

Indexed keywords

CISPLATIN; DOCETAXEL; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; IFOSFAMIDE; NAVELBINE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LUNG CARCINOMA; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PALLIATIVE THERAPY; PRIORITY JOURNAL; PULMONARY PLEOMORPHIC CARCINOMA; REPEATED DRUG DOSE; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; RECURRENCE; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 34548494404     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.05.006     Document Type: Article

References (15)

1. Beasley M.B., Brambilla E., and Travis W.D. The 2004 World Health Organization classification of lung tumors. Semin Roentgenol 40 (2005) 90-97
2. Fishback N.F., Travis W.D., Moran C.A., Guinee Jr. D.G., McCarthy W.F., and Koss M.N. Pleomorphic (spindle/giant cell) carcinoma of the lung. A clinicopathologic correlation of 78 cases. Cancer 73 12 (1994) 2936-2945
3. Nakajima M., Kasai T., Hashimoto H., Iwata Y., and Manabe H. Sarcomatoid carcinoma of the lung: a clinicopathologic study of 37 cases. Cancer 86 (1999) 608-616
4. Pelosi G., Fraggetta F., Nappi O., Pastorino U., Maisonneuve P., Pasini F., et al. Pleomorphic carcinomas of the lung show a selective distribution of gene products involved in cell differentiation, cell cycle control, tumor growth, and tumor cell motility: a clinicopathologic and immunohistochemical study of 31 cases. Am J Surg Pathol 27 (2003) 1203-1215
5. Ro J.Y., Chen J.L., Lee J.S., Sahin A.A., Ordonez N.G., and Ayala A.G. Sarcomatoid carcinoma of the lung. Immunohistochemical and ultrastructural studies of 14 cases. Cancer 69 (1992) 376-386
6. Rossi G., Cavazza A., Sturm N., Migaldi M., Facciolongo N., Longo L., et al. Pulmonary carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements: a clinicopathologic and immunohistochemical study of 75 cases. Am J Surg Pathol 27 (2003) 311-324
7. Aketa A., Yamada G., Aketa K., Ohnishi T., Takahashi Y., Kudoh K., et al. Two younger male patients with rapidly progressing pulmonary pleomorphic carcinoma. Nihon Kokyuki Gakkai Zasshi 42 (2004) 164-169
8. Ishibashi H., Akamatsu H., and Sunamori M. Gingival metastasis of pulmonary pleomorphic carcinoma; report of a case. Kyobu Geka 58 (2005) 410-414
9. Raveglia F., Mezzetti M., Panigalli T., Furia S., Giuliani L., Conforti S., et al. Personal experience in surgical management of pulmonary pleomorphic carcinoma. Ann Thorac Surg 78 (2004) 1742-1747
10. Segawa M., Kusajima Y., and Saito K. Pleomorphic carcinoma of the lung rapidly developed multiple metastases after surgery. Kyobu Geka 59 (2006) 387-391
11. Tamura M., Dohhba S., Funaki K., Sasaki S., Michiwa Y., Kurosaka Y., et al. Pulmonary pleomorphic carcinoma; report of 2 cases. Kyobu Geka 59 (2006) 585-589
12. Chang Y.L., Lee Y.C., Shih J.Y., and Wu C.T. Pulmonary pleomorphic (spindle) cell carcinoma: peculiar clinicopathologic manifestations different from ordinary non-small cell carcinoma. Lung Cancer 34 (2001) 91-97
13. Miller A.B., Hoogstraten B., Staquet M., and Winkler A. Reporting results of cancer treatment. Cancer 47 (1981) 207-214
14. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
15. Oken M.M., Creech R.H., Tormey D.C., Horton J., Davis T.E., McFadden E.T., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5 (1982) 649-655